Skip to main content
IOS Press Open Library logoLink to IOS Press Open Library
. 2019 Oct 11;9(4):825. doi: 10.3233/JPD-199003

The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

Diane Stephenson, Derek Hill, Jesse M Cedarbaum, Maria Tome, Spiros Vamvakas, Klaus Romero, Daniela J Conrado, David T Dexter, John Seibyl, Danna Jennings, Timothy Nicholas, Dawn Matthews, Zhiyong Xie, Syed Imam, Paul Maguire, David Russell, Mark Forrest Gordon, Glenn T Stebbins, Ed Somer, Jill Gallagher, Arthur Roach, Peter Basseches, Donald Grosset, Ken Marek; on behalf of the Critical Path for Parkinson’s Consortium
PMCID: PMC6878913  PMID: 31524182

[Journal of Parkinson’s Disease, 9(3) (2019), 553–563, DOI 10.3233/JPD-191648]

https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd191648

On page 560, the following Disclaimer was missing from the published article:

The findings and conclusions in this publications by the authors from US Food and Drug Administration are those of the authors and do not necessarily represent the views of the FDA.


Articles from Journal of Parkinson's Disease are provided here courtesy of IOS Press

RESOURCES